Page 18, line 29, after "-Cys", insert -- [SEQ ID NO: 2] --.

Page 18, line 31, after "-Cys", insert -- [SEQ ID NO: 9] --.

Page 20, line 25, after "-Glu-)", insert -- [SEQ ID NO: 1] --.

Page 20, line 26, after "-Cys)", insert -- [SEQ ID NO: 3] --.

Page 21, line 4, after "-Glu", insert -- [SEQ ID NO: 1] --.

Page 21, line 5, after "-Cys", insert -- [SEQ ID NO: 2] --.

Page 21, line 6, after "-Cys)", insert -- [SEQ ID NO: 3] --.

Page 21, line 8, after "-Glu", insert -- [SEQ ID NO: 1] --.

Page 21, line 11, after "-Glu)", insert -- [SEQ ID NO: 1] --.

Please enter the attached Abstract of the Disclosure on the attached page.

In the Claims

Add new claims 15-43 as follows.

15. A method for treating hypergastrinemia in a mammal comprising administering to said mammal with hypergastrinemia an effective amount of an immunogenic composition that reduces the circulating hormone, gastrin.

16. The method according to claim 15, wherein said immunogenic composition comprises a peptide conjugated to an immunogenic carrier and a pharmaceutically acceptable carrier.

17. The method according to claim 16, wherein said immunogenic composition is selected from the group consisting of a G17 peptide fragment SEQ ID NO: 1 linked by an amino acid spacer to an immunogenic carrier; a G34 peptide fragment SEQ ID NO: 2 linked by an amino acid spacer to an immunogenic carrier; a combination of said G17 and G34 fragments linked by an amino acid spacer to an

immunogenic carrier.

18. The method according to claim 17, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.

19. The method according to claim 15, wherein said composition comprises anti-gastrin antibodies that bind to gastrin.

20. The method according to claim 19, wherein said antibodies are purified or humanized.

21. The method according to claim 19, wherein said antibodies bind to heptadecagastrin G17.

22. The method according to claim 19, wherein said antibodies bind to tetratriacontagastrin G34.

23. The method according to claim 19, wherein said antibodies comprise a mixture of antibodies that bind to heptadecagastrin G17 and antibodies that bind to tetratriacontagastrin G34.

24. The method according to claim 15, further comprising administering to said mammal an agent selected from the group consisting of a histamine $H_2$ receptor blocker and a proton pump inhibitor.

25. The method according to claim 24, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.

26. The method according to claim 24, wherein said inhibitor is

selected from the group consisting of omeprazole, lansoprazole and pantoprazole.

27. The method according to claim 24, wherein said mammal is administered said immunogenic composition before said agent.

28. The method according to claim 24, wherein said composition and agent are co-administered to said mammal.

29. The method according to claim 15, wherein said hypergastrinemia is associated with a condition selected from the group consisting of pernicious anemia, a gastric tumor, a gastric cancer, and a course of therapy with a substance that results in increased gastrin levels.

30. A method for reducing the side effects of anti-ulcer agents in a mammal comprising administering to a mammal receiving an agent that suppresses gastric acid production or secretion an effective amount of an immunogenic composition that reduces the circulating hormone, gastrin.

31. The method according to claim 30, wherein said immunogenic composition comprises a peptide conjugated to an immunogenic carrier and a pharmaceutically acceptable carrier.

32. The method according to claim 31, wherein said immunogenic composition is selected from the group consisting of a G17 peptide fragment SEQ ID NO: 1 linked by an amino acid spacer to an immunogenic carrier; a G34 peptide fragment SEQ ID NO: 2 linked by an amino acid spacer to an immunogenic carrier; a combination of said G17 and G34 fragments linked by an amino acid spacer to an immunogenic carrier.

33. The method according to claim 32, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.

34. The method according to claim 30, wherein said composition comprises anti-gastrin antibodies that bind to gastrin.

35. The method according to claim 34, wherein said antibodies are purified or humanized.

36. The method according to claim 34, wherein said antibodies bind to heptadecagastrin G17.

37. The method according to claim 34, wherein said antibodies bind to tetratriacontagastrin G34.

38. The method according to claim 34, wherein said antibodies comprise a mixture of antibodies that bind to heptadecagastrin G17 and antibodies that bind to tetratriacontagastrin G34.

39. The method according to claim 30, wherein said agent is selected from the group consisting of a histamine $H_2$ receptor blocker and a proton pump inhibitor.

40. The method according to claim 39, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.

41. The method according to claim 39, wherein said inhibitor is selected from the group consisting of omeprazole, lansoprazole and pantoprazole.

42. The method according to claim 30, wherein said mammal is administered said immunogenic composition before said agent.

43. The method according to claim 30, wherein said composition and agent are co-administered to said mammal.

REMARKS

Upon entry of this preliminary amendment, the claims pending are claims 7 and 15-43. New claims 15-43 are supported throughout the specification and by original claims 1-14.

Specification pages 18, 20 and 21 are amended to insert SEQ ID NOS.